Phase 0 Clinical Chemoprevention Trial of the AKT Inhibitor SR13668

PURPOSE: SR13668, an orally active AKT pathway inhibitor, has demonstrated cancer chemopreventive potential in preclinical studies. To accelerate the clinical development of this promising agent, we designed and conducted the first-ever phase 0 chemoprevention trial to evaluate and compare the effec...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Reid, Joel M., Walden, Chad, Qin, Rui, Allen Ziegler, Katie L., Haslam, John L., Rajewski, Roger A., Warndahl, Roger, Fitting, Cindy L., Boring, Daniel, Szabo, Eva, Crowell, James, Perloff, Marjorie, Jong, Ling, Mandrekar, Sumithra J., Ames, Matthew M., Limburg, Paul J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2011
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3061470/
https://ncbi.nlm.nih.gov/pubmed/21372034
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-10-0313
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi